SUN PRAIRIE, Wis., Feb. 16, 2025 /PRNewswire/ — Independent Pharmacy Cooperative (IPC), the leading Group Purchasing Organization (GPO) for independent pharmacies nationwide, is thrilled to announce a groundbreaking cooperation agreement with Legacy Pharmacy Group (LPG). This strategic partnership aims to enhance the capabilities and offerings for both organizations, benefiting our members and advancing independent pharmacy.
Why This Agreement Matters:
Quote from Marc Essensa, CEO, IPC:
“This partnership is a big step for IPC and LPG community pharmacies. This collaboration creates new opportunities to grow, improve patient care and strengthen the future of community pharmacy. Together, we’re building a more resilient and innovative healthcare system.”
Quote from Ritesh Shah, CEO, LPG:
“This strategic relationship will bring huge advantages for our Legacy pharmacies. We are excited for the new partnership, and more importantly, we will make a positive and meaningful impact on the communities our pharmacies serve.”
IPC and LPG are committed to supporting independent pharmacies and the patients they serve. We’re excited about this collaboration and the impact it can have on our members and their communities.
About Independent Pharmacy Cooperative (IPC): IPC is a member-owned GPO dedicated to supporting independent pharmacies across the United States. With a focus on advocacy, purchasing power, and operational excellence, IPC empowers pharmacies to thrive in an ever-evolving healthcare landscape.
About Legacy Pharmacy Group (LPG): Legacy Pharmacy Group is a leading pharmacy solutions provider dedicated to supporting independent pharmacies in a highly competitive business environment. Headquartered in Hackensack, New Jersey, LPG has evolved into the tristate area’s largest group purchasing organization for independent pharmacies providing the most progressive and effective programs and services to put profit back in the independent pharmacy.
SOURCE IPC (Independent Pharmacy Cooperative)
New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance…
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…